Known hypersensitivity to Gelofusine.

In common with other colloidal plasma volume expanders, mild urticarial reactions have been reported.

Severe anaphylactoid reactions following use of Gelofusine occur in humans with a reported incidence of between 1 in 6,000 and 1 in 13,000 units administered. Such reactions are related to the release of vasoactive substances and can be assumed to be more frequent and particularly hazardous in animals with known allergic conditions such as asthma. Treatment: The infusion of Gelofusine should be stopped. Further treatment will depend upon the severity of the anaphylactic reaction. Administration of supplemental oxygen; an alternative intravenous fluid; and the parenteral administration of adrenalin and an antihistamine should be considered.

Gelofusine should be given with care to animals who are susceptible to circulatory overloading (e.g. severe congestive cardiac failure or renal failure with oliguria or anuria) since excessive volumes may give rise to circulatory overload and electrolyte imbalance. Treatment: The infusion should be stopped and the animal treated symptomatically. Electrolytes should be monitored. If necessary a diuretic may be given to promote fluid loss. Decreased urinary output secondary to shock is not a contraindication unless there is no improvement in urine output after the initial dose of Gelofusine.

It should not be used to prevent falls in arterial pressure consequent on spinal or epidural anaesthesia.

Pregnancy and lactation: There is very little information available on the use of plasma substitutes in pregnant or lactating animals. As with all drugs, the benefits and risks of use should be assessed in light of the animal's condition: Gelofusine may be used in the initial treatment of blood loss during pregnancy where plasma volume replacement is needed.

General precautions: For animal treatment only.

Withdrawal period: Not to be used in horses intended for human consumption.